ID   ATPA_HUMAN              Reviewed;         553 AA.
AC   P25705; A8K092; B4DY56; K7ENP3; Q53XX6; Q8IXV2; Q96FB4; Q96HW2; Q96IR6;
AC   Q9BTV8;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   28-JAN-2026, entry version 263.
DE   RecName: Full=ATP synthase F(1) complex subunit alpha, mitochondrial {ECO:0000305};
DE   AltName: Full=ATP synthase F1 subunit alpha {ECO:0000312|HGNC:HGNC:823};
DE   Flags: Precursor;
GN   Name=ATP5F1A {ECO:0000312|HGNC:HGNC:823};
GN   Synonyms=ATP5A, ATP5A1 {ECO:0000312|HGNC:HGNC:823}, ATP5AL2
GN   {ECO:0000312|HGNC:HGNC:823}, ATPM {ECO:0000312|HGNC:HGNC:823};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lung tumor;
RX   PubMed=1830491; DOI=10.1016/0167-4781(91)90183-m;
RA   Kataoka H., Biswas C.;
RT   "Nucleotide sequence of a cDNA for the alpha subunit of human mitochondrial
RT   ATP synthase.";
RL   Biochim. Biophys. Acta 1089:393-395(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Retinoblastoma;
RX   PubMed=8428659; DOI=10.1016/0378-1119(93)90124-l;
RA   Godbout R., Bisgrove D.A., Honore L.H., Day R.S. III;
RT   "Amplification of the gene encoding the alpha-subunit of the mitochondrial
RT   ATP synthase complex in a human retinoblastoma cell line.";
RL   Gene 123:195-201(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RC   TISSUE=Colon tumor;
RX   PubMed=8086450; DOI=10.1016/0167-4781(94)90255-0;
RA   Akiyama S., Endo H., Inohara N., Ohta S., Kagawa Y.;
RT   "Gene structure and cell type-specific expression of the human ATP synthase
RT   alpha subunit.";
RL   Biochim. Biophys. Acta 1219:129-140(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Small intestine, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D.,
RA   Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J.,
RA   Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L.,
RA   Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A.,
RA   Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C.,
RA   Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, Retina, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE [LARGE SCALE ANALYSIS] OF 44-59.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19892738; DOI=10.1073/pnas.0908958106;
RA   Xu G., Shin S.B., Jaffrey S.R.;
RT   "Global profiling of protease cleavage sites by chemoselective labeling of
RT   protein N-termini.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:19310-19315(2009).
RN   [9]
RP   PROTEIN SEQUENCE OF 46-83; 89-103; 134-161; 176-182; 219-230; 242-252;
RP   306-316; 335-347; 403-416; 435-463 AND 507-527, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [10]
RP   PROTEIN SEQUENCE OF 46-73; 104-123; 134-161; 219-230; 232-239; 306-316;
RP   335-347; 403-416; 442-463 AND 507-527, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (MAR-2005) to UniProtKB.
RN   [11]
RP   PROTEIN SEQUENCE OF 134-141 AND 335-339.
RC   TISSUE=Heart;
RX   PubMed=7498159; DOI=10.1002/elps.11501601192;
RA   Kovalyov L.I., Shishkin S.S., Efimochkin A.S., Kovalyova M.A.,
RA   Ershova E.S., Egorov T.A., Musalyamov A.K.;
RT   "The major protein expression profile and two-dimensional protein database
RT   of human heart.";
RL   Electrophoresis 16:1160-1169(1995).
RN   [12]
RP   INTERACTION WITH PLG, IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=10077593; DOI=10.1073/pnas.96.6.2811;
RA   Moser T.L., Stack M.S., Asplin I., Enghild J.J., Hojrup P., Everitt L.,
RA   Hubchak S., Schnaper H.W., Pizzo S.V.;
RT   "Angiostatin binds ATP synthase on the surface of human endothelial
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2811-2816(1999).
RN   [13]
RP   INTERACTION WITH ATPAF2.
RX   PubMed=11410595; DOI=10.1074/jbc.m104133200;
RA   Wang Z.-G., White P.S., Ackerman S.H.;
RT   "Atp11p and Atp12p are assembly factors for the F(1)-ATPase in human
RT   mitochondria.";
RL   J. Biol. Chem. 276:30773-30778(2001).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [15]
RP   INTERACTION WITH HRG, IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19285951; DOI=10.1016/j.bbamem.2009.03.005;
RA   Ohta T., Ikemoto Y., Usami A., Koide T., Wakabayashi S.;
RT   "High affinity interaction between histidine-rich glycoprotein and the cell
RT   surface type ATP synthase on T-cells.";
RL   Biochim. Biophys. Acta 1788:1099-1107(2009).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-161; LYS-261; LYS-434; LYS-498;
RP   LYS-506 AND LYS-539, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-166, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   INTERACTION WITH BLOC1S1, AND ACETYLATION.
RX   PubMed=22309213; DOI=10.1042/bj20120118;
RA   Scott I., Webster B.R., Li J.H., Sack M.N.;
RT   "Identification of a molecular component of the mitochondrial acetyl
RT   transferase program; a novel role for GCN5L1.";
RL   Biochem. J. 443:655-661(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-53; SER-65; SER-76; SER-166
RP   AND SER-184, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [23]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=30146159; DOI=10.1016/j.cell.2018.07.032;
RA   Qi B., Han M.;
RT   "Microbial Siderophore Enterobactin Promotes Mitochondrial Iron Uptake and
RT   Development of the Host via Interaction with ATP Synthase.";
RL   Cell 175:571-582(2018).
RN   [24] {ECO:0007744|PDB:8H9E, ECO:0007744|PDB:8H9I, ECO:0007744|PDB:8H9L, ECO:0007744|PDB:8H9P, ECO:0007744|PDB:8H9S, ECO:0007744|PDB:8H9T, ECO:0007744|PDB:8H9U, ECO:0007744|PDB:8H9V}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.53 ANGSTROMS) OF 44-553 IN COMPLEX WITH
RP   ATP AND MG(2+), IDENTIFICATION IN THE ATP SYNTHASE COMPLEX, FUNCTION, AND
RP   SUBUNIT.
RX   PubMed=37244256; DOI=10.1016/j.molcel.2023.04.029;
RA   Lai Y., Zhang Y., Zhou S., Xu J., Du Z., Feng Z., Yu L., Zhao Z., Wang W.,
RA   Tang Y., Yang X., Guddat L.W., Liu F., Gao Y., Rao Z., Gong H.;
RT   "Structure of the human ATP synthase.";
RL   Mol. Cell 83:2137-2147.e4(2023).
RN   [25]
RP   VARIANT MC5DN4B CYS-329.
RX   PubMed=23599390; DOI=10.1093/brain/awt086;
RA   Jonckheere A.I., Renkema G.H., Bras M., van den Heuvel L.P., Hoischen A.,
RA   Gilissen C., Nabuurs S.B., Huynen M.A., de Vries M.C., Smeitink J.A.,
RA   Rodenburg R.J.;
RT   "A complex V ATP5A1 defect causes fatal neonatal mitochondrial
RT   encephalopathy.";
RL   Brain 136:1544-1554(2013).
RN   [26]
RP   VARIANT COXPD22 CYS-321, AND INVOLVEMENT IN COXPD22.
RX   PubMed=23596069; DOI=10.1212/wnl.0b013e3182918c40;
RA   Lieber D.S., Calvo S.E., Shanahan K., Slate N.G., Liu S., Hershman S.G.,
RA   Gold N.B., Chapman B.A., Thorburn D.R., Berry G.T., Schmahmann J.D.,
RA   Borowsky M.L., Mueller D.M., Sims K.B., Mootha V.K.;
RT   "Targeted exome sequencing of suspected mitochondrial disorders.";
RL   Neurology 80:1762-1770(2013).
RN   [27]
RP   VARIANT MC5DN4A HIS-207, AND INVOLVEMENT IN MC5DN4A.
RX   PubMed=34483339; DOI=10.1038/s41431-021-00956-0;
RA   Lines M.A., Cuillerier A., Chakraborty P., Naas T., Duque Lasio M.L.,
RA   Michaud J., Pileggi C., Harper M.E., Burelle Y., Toler T.L., Sondheimer N.,
RA   Crawford H.P., Millan F., Geraghty M.T.;
RT   "A recurrent de novo ATP5F1A substitution associated with neonatal complex
RT   V deficiency.";
RL   Eur. J. Hum. Genet. 29:1719-1724(2021).
RN   [28]
RP   VARIANTS MC5DN4A GLN-182; HIS-207 AND PHE-346, AND INVOLVEMENT IN MC5DN4A.
RX   PubMed=34954817; DOI=10.1002/ana.26293;
RA   Zech M., Kopajtich R., Steinbruecker K., Bris C., Gueguen N.,
RA   Feichtinger R.G., Achleitner M.T., Duzkale N., Perivier M., Koch J.,
RA   Engelhardt H., Freisinger P., Wagner M., Brunet T., Berutti R., Smirnov D.,
RA   Navaratnarajah T., Rodenburg R.J.T., Pais L.S., Austin-Tse C., O'Leary M.,
RA   Boesch S., Jech R., Bakhtiari S., Jin S.C., Wilbert F., Kruer M.C.,
RA   Wortmann S.B., Eckenweiler M., Mayr J.A., Distelmaier F., Steinfeld R.,
RA   Winkelmann J., Prokisch H.;
RT   "Variants in Mitochondrial ATP Synthase Cause Variable Neurologic
RT   Phenotypes.";
RL   Ann. Neurol. 91:225-237(2022).
CC   -!- FUNCTION: Subunit alpha, of the mitochondrial membrane ATP synthase
CC       complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP
CC       in the presence of a proton gradient across the membrane which is
CC       generated by electron transport complexes of the respiratory chain
CC       (Probable). ATP synthase complex consist of a soluble F(1) head domain
CC       - the catalytic core - and a membrane F(1) domain - the membrane proton
CC       channel (PubMed:37244256). These two domains are linked by a central
CC       stalk rotating inside the F(1) region and a stationary peripheral stalk
CC       (PubMed:37244256). During catalysis, ATP synthesis in the catalytic
CC       domain of F(1) is coupled via a rotary mechanism of the central stalk
CC       subunits to proton translocation (Probable). In vivo, can only
CC       synthesize ATP although its ATP hydrolase activity can be activated
CC       artificially in vitro (By similarity). With the catalytic subunit beta
CC       (ATP5F1B), forms the catalytic core in the F(1) domain
CC       (PubMed:37244256). Subunit alpha does not bear the catalytic high-
CC       affinity ATP-binding sites (Probable). Binds the bacterial siderophore
CC       enterobactin and can promote mitochondrial accumulation of
CC       enterobactin-derived iron ions (PubMed:30146159).
CC       {ECO:0000250|UniProtKB:P19483, ECO:0000269|PubMed:30146159,
CC       ECO:0000269|PubMed:37244256, ECO:0000305|PubMed:37244256}.
CC   -!- SUBUNIT: Homotrimer (PubMed:37244256). Component of the ATP synthase
CC       complex composed at least of ATP5F1A/subunit alpha, ATP5F1B/subunit
CC       beta, ATP5MC1/subunit c (homooctamer), MT-ATP6/subunit a, MT-
CC       ATP8/subunit 8, ATP5ME/subunit e, ATP5MF/subunit f, ATP5MG/subunit g,
CC       ATP5MK/subunit k, ATP5MJ/subunit j, ATP5F1C/subunit gamma,
CC       ATP5F1D/subunit delta, ATP5F1E/subunit epsilon, ATP5PF/subunit F6,
CC       ATP5PB/subunit b, ATP5PD/subunit d, ATP5PO/subunit OSCP
CC       (PubMed:37244256). ATP synthase complex consists of a soluble F(1) head
CC       domain (subunits alpha(3) and beta(3)) - the catalytic core - and a
CC       membrane F(0) domain - the membrane proton channel (subunits c, a, 8,
CC       e, f, g, k and j) (PubMed:37244256). These two domains are linked by a
CC       central stalk (subunits gamma, delta, and epsilon) rotating inside the
CC       F1 region and a stationary peripheral stalk (subunits F6, b, d, and
CC       OSCP) (PubMed:37244256). Interacts with ATPAF2 (PubMed:11410595).
CC       Interacts with HRG; the interaction occurs on the surface of T-cells
CC       and alters the cell morphology when associated with concanavalin (in
CC       vitro) (PubMed:19285951). Interacts with PLG (angiostatin peptide); the
CC       interaction inhibits most of the angiogenic properties of angiostatin
CC       (PubMed:10077593). Interacts with BLOC1S1 (PubMed:22309213). Interacts
CC       with BCL2L1 isoform BCL-X(L); the interaction mediates the association
CC       of BCL2L1 isoform BCL-X(L) with the mitochondrial membrane F(1)F(0) ATP
CC       synthase and enhances neurons metabolic efficiency (By similarity).
CC       Interacts with CLN5 and PPT1 (By similarity). Interacts with S100A1;
CC       this interaction increases F1-ATPase activity (By similarity).
CC       Interacts with ABCB7; this interaction allows the regulation of
CC       cellular iron homeostasis and cellular reactive oxygen species (ROS)
CC       levels in cardiomyocytes (By similarity).
CC       {ECO:0000250|UniProtKB:P15999, ECO:0000250|UniProtKB:Q03265,
CC       ECO:0000269|PubMed:10077593, ECO:0000269|PubMed:11410595,
CC       ECO:0000269|PubMed:19285951, ECO:0000269|PubMed:22309213,
CC       ECO:0000269|PubMed:37244256}.
CC   -!- INTERACTION:
CC       P25705; P06576: ATP5F1B; NbExp=8; IntAct=EBI-351437, EBI-356231;
CC       P25705; P24539: ATP5PB; NbExp=11; IntAct=EBI-351437, EBI-1044810;
CC       P25705; P18859: ATP5PF; NbExp=7; IntAct=EBI-351437, EBI-2606700;
CC       P25705; P48047: ATP5PO; NbExp=5; IntAct=EBI-351437, EBI-355815;
CC       P25705; Q8N5M1: ATPAF2; NbExp=4; IntAct=EBI-351437, EBI-1166928;
CC       P25705; P78537: BLOC1S1; NbExp=2; IntAct=EBI-351437, EBI-348630;
CC       P25705; P42858: HTT; NbExp=3; IntAct=EBI-351437, EBI-466029;
CC       P25705; Q9NTG7: SIRT3; NbExp=2; IntAct=EBI-351437, EBI-724621;
CC       P25705; P63104: YWHAZ; NbExp=4; IntAct=EBI-351437, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:30146159}.
CC       Mitochondrion inner membrane {ECO:0000250|UniProtKB:P19483}; Peripheral
CC       membrane protein {ECO:0000250|UniProtKB:P19483}; Matrix side
CC       {ECO:0000250|UniProtKB:P19483}. Cell membrane
CC       {ECO:0000269|PubMed:10077593}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:10077593}; Extracellular side
CC       {ECO:0000269|PubMed:10077593}. Note=Colocalizes with HRG on the cell
CC       surface of T-cells (PubMed:19285951). {ECO:0000269|PubMed:19285951}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P25705-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P25705-2; Sequence=VSP_045129;
CC       Name=3;
CC         IsoId=P25705-3; Sequence=VSP_054688;
CC   -!- TISSUE SPECIFICITY: Fetal lung, heart, liver, gut and kidney. Expressed
CC       at higher levels in the fetal brain, retina and spinal cord.
CC       {ECO:0000269|PubMed:8428659}.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- PTM: Acetylated on lysine residues. BLOC1S1 is required for
CC       acetylation. {ECO:0000269|PubMed:22309213}.
CC   -!- DISEASE: Combined oxidative phosphorylation deficiency 22 (COXPD22)
CC       [MIM:616045]: A mitochondrial disorder characterized by intrauterine
CC       growth retardation, microcephaly, hypotonia, pulmonary hypertension,
CC       failure to thrive, encephalopathy, and heart failure.
CC       {ECO:0000269|PubMed:23596069}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Mitochondrial complex V deficiency, nuclear type 4A (MC5DN4A)
CC       [MIM:620358]: An autosomal dominant mitochondrial disorder
CC       characterized by failure to thrive, feeding difficulties,
CC       hyperlactatemia, hyperammonemia, and increased serum alanine levels.
CC       Some affected individuals show spontaneous resolution of the symptoms
CC       in early childhood and have subsequent normal growth and development,
CC       whereas others show developmental delay with impaired intellectual
CC       development and movement abnormalities, including dystonia, ataxia, or
CC       spasticity. {ECO:0000269|PubMed:34483339, ECO:0000269|PubMed:34954817}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Mitochondrial complex V deficiency, nuclear type 4B (MC5DN4B)
CC       [MIM:615228]: An autosomal recessive mitochondrial disorder
CC       characterized by severe neonatal encephalopathy resulting in death in
CC       the first weeks of life. Affected individuals do not show dysmorphic
CC       features or organomegaly, and manifest neurologic features such as
CC       irritability, a high-pitched cry, a horizontal and vertical nystagmus,
CC       abnormal primitive reflexes, and tonus dysregulation. Post-mortem
CC       anatomopathological examination shows extensive cerebral damage,
CC       hypoplastic lungs, and renal and skeletal lesions.
CC       {ECO:0000269|PubMed:23599390}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The siderophore enterobactin (Ent) produced by enteric
CC       bacteria binds Fe(3+) and helps bacteria scavenge iron ions from the
CC       environment (PubMed:30146159). As a consequence, the mammalian
CC       siderocalin LCN2 plays an important role in defense against bacterial
CC       infections by sequestering iron bound to microbial siderophores. LCN2
CC       can also bind iron bound to endogenous or nutrient-derived iron
CC       chelators and plays an important role in cellular iron homeostasis.
CC       Enterobactin produced by non-pathogenic E.coli strains can facilitate
CC       mitochondrial iron assimilation, suggesting that iron bound to
CC       siderophores from non-pathogenic bacteria may contribute to iron
CC       absorption by the host (PubMed:30146159). {ECO:0000269|PubMed:30146159,
CC       ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the ATPase alpha/beta chains family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X59066; CAA41789.1; -; mRNA.
DR   EMBL; X65460; CAA46452.1; -; mRNA.
DR   EMBL; D14710; BAA03531.1; -; mRNA.
DR   EMBL; D28126; BAA05672.1; -; Genomic_DNA.
DR   EMBL; BT007209; AAP35873.1; -; mRNA.
DR   EMBL; AK092735; BAG52604.1; -; mRNA.
DR   EMBL; AK289457; BAF82146.1; -; mRNA.
DR   EMBL; AK302272; BAG63618.1; -; mRNA.
DR   EMBL; AC012569; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC003119; AAH03119.1; -; mRNA.
DR   EMBL; BC007299; AAH07299.1; -; mRNA.
DR   EMBL; BC008028; AAH08028.2; -; mRNA.
DR   EMBL; BC011384; AAH11384.1; -; mRNA.
DR   EMBL; BC016046; AAH16046.1; -; mRNA.
DR   EMBL; BC019310; AAH19310.1; -; mRNA.
DR   EMBL; BC039135; AAH39135.2; -; mRNA.
DR   EMBL; BC064562; AAH64562.1; -; mRNA.
DR   EMBL; BC067385; AAH67385.1; -; mRNA.
DR   CCDS; CCDS11927.1; -. [P25705-1]
DR   CCDS; CCDS58620.1; -. [P25705-2]
DR   CCDS; CCDS59315.1; -. [P25705-3]
DR   PIR; S17193; PWHUA.
DR   RefSeq; NP_001001935.1; NM_001001935.3. [P25705-2]
DR   RefSeq; NP_001001937.1; NM_001001937.2. [P25705-1]
DR   RefSeq; NP_001244263.1; NM_001257334.2. [P25705-3]
DR   RefSeq; NP_001244264.1; NM_001257335.2. [P25705-2]
DR   RefSeq; NP_004037.1; NM_004046.6. [P25705-1]
DR   PDB; 8H9E; EM; 2.53 A; A/B/C=44-553.
DR   PDB; 8H9I; EM; 2.77 A; A/B/C=44-553.
DR   PDB; 8H9L; EM; 2.61 A; A/B/C=44-553.
DR   PDB; 8H9P; EM; 3.02 A; A/B/C=44-553.
DR   PDB; 8H9S; EM; 2.53 A; A/B/C=44-553.
DR   PDB; 8H9T; EM; 2.77 A; A/B/C=44-553.
DR   PDB; 8H9U; EM; 2.61 A; A/B/C=44-553.
DR   PDB; 8H9V; EM; 3.02 A; A/B/C=44-553.
DR   PDB; 8KI3; EM; 2.89 A; A/B/C=44-553.
DR   PDBsum; 8H9E; -.
DR   PDBsum; 8H9I; -.
DR   PDBsum; 8H9L; -.
DR   PDBsum; 8H9P; -.
DR   PDBsum; 8H9S; -.
DR   PDBsum; 8H9T; -.
DR   PDBsum; 8H9U; -.
DR   PDBsum; 8H9V; -.
DR   PDBsum; 8KI3; -.
DR   AlphaFoldDB; P25705; -.
DR   EMDB; EMD-34564; -.
DR   EMDB; EMD-34568; -.
DR   EMDB; EMD-34572; -.
DR   EMDB; EMD-34576; -.
DR   EMDB; EMD-34580; -.
DR   EMDB; EMD-34581; -.
DR   EMDB; EMD-34582; -.
DR   EMDB; EMD-34583; -.
DR   EMDB; EMD-37251; -.
DR   SMR; P25705; -.
DR   BioGRID; 106987; 610.
DR   ComplexPortal; CPX-6151; Mitochondrial proton-transporting ATP synthase complex.
DR   CORUM; P25705; -.
DR   DIP; DIP-32871N; -.
DR   FunCoup; P25705; 1855.
DR   IntAct; P25705; 223.
DR   MINT; P25705; -.
DR   STRING; 9606.ENSP00000381736; -.
DR   ChEMBL; CHEMBL2062351; -.
DR   DrugBank; DB07384; 1-ACETYL-2-CARBOXYPIPERIDINE.
DR   DrugBank; DB11638; Artenimol.
DR   DrugBank; DB07394; AUROVERTIN B.
DR   DrugBank; DB01119; Diazoxide.
DR   DrugBank; DB08629; N1-(2-AMINO-4-METHYLPENTYL)OCTAHYDRO-PYRROLO[1,2-A] PYRIMIDINE.
DR   DrugBank; DB08399; Piceatannol.
DR   DrugBank; DB04216; Quercetin.
DR   TCDB; 3.A.2.1.15; the h+- or na+-translocating f-type, v-type and a-type atpase (f-atpase) superfamily.
DR   GlyCosmos; P25705; 5 sites, 1 glycan.
DR   GlyGen; P25705; 7 sites, 1 O-linked glycan (6 sites).
DR   iPTMnet; P25705; -.
DR   MetOSite; P25705; -.
DR   PhosphoSitePlus; P25705; -.
DR   SwissPalm; P25705; -.
DR   BioMuta; ATP5A1; -.
DR   DMDM; 114517; -.
DR   OGP; P25705; -.
DR   REPRODUCTION-2DPAGE; P25705; -.
DR   CPTAC; CPTAC-171; -.
DR   CPTAC; CPTAC-172; -.
DR   jPOST; P25705; -.
DR   MassIVE; P25705; -.
DR   PaxDb; 9606-ENSP00000381736; -.
DR   PeptideAtlas; P25705; -.
DR   PRIDE; P25705; -.
DR   ProteomicsDB; 1832; -.
DR   ProteomicsDB; 54283; -. [P25705-1]
DR   Pumba; P25705; -.
DR   TopDownProteomics; P25705-1; -. [P25705-1]
DR   Antibodypedia; 22447; 353 antibodies from 36 providers.
DR   DNASU; 498; -.
DR   Ensembl; ENST00000282050.6; ENSP00000282050.2; ENSG00000152234.17. [P25705-1]
DR   Ensembl; ENST00000398752.11; ENSP00000381736.5; ENSG00000152234.17. [P25705-1]
DR   Ensembl; ENST00000590665.5; ENSP00000467037.1; ENSG00000152234.17. [P25705-3]
DR   Ensembl; ENST00000593152.6; ENSP00000465477.2; ENSG00000152234.17. [P25705-2]
DR   GeneID; 498; -.
DR   KEGG; hsa:498; -.
DR   MANE-Select; ENST00000398752.11; ENSP00000381736.5; NM_004046.6; NP_004037.1.
DR   UCSC; uc010dnl.2; human. [P25705-1]
DR   AGR; HGNC:823; -.
DR   ClinPGx; PA25115; -.
DR   CTD; 498; -.
DR   DisGeNET; 498; -.
DR   GeneCards; ATP5F1A; -.
DR   HGNC; HGNC:823; ATP5F1A.
DR   HPA; ENSG00000152234; Tissue enhanced (tongue).
DR   MalaCards; ATP5F1A; -.
DR   MIM; 164360; gene.
DR   MIM; 615228; phenotype.
DR   MIM; 616045; phenotype.
DR   MIM; 620358; phenotype.
DR   OpenTargets; ENSG00000152234; -.
DR   Orphanet; 254913; Isolated ATP synthase deficiency.
DR   VEuPathDB; HostDB:ENSG00000152234; -.
DR   eggNOG; KOG1353; Eukaryota.
DR   GeneTree; ENSGT00550000074846; -.
DR   HOGENOM; CLU_010091_2_1_1; -.
DR   InParanoid; P25705; -.
DR   OMA; INQRDNW; -.
DR   OrthoDB; 9805536at2759; -.
DR   PAN-GO; P25705; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; P25705; -.
DR   BioCyc; MetaCyc:HS07800-MONOMER; -.
DR   PathwayCommons; P25705; -.
DR   Reactome; R-HSA-1268020; Mitochondrial protein import.
DR   Reactome; R-HSA-163210; Formation of ATP by chemiosmotic coupling.
DR   Reactome; R-HSA-8949613; Cristae formation.
DR   Reactome; R-HSA-9837999; Mitochondrial protein degradation.
DR   SignaLink; P25705; -.
DR   SIGNOR; P25705; -.
DR   Agora; ENSG00000152234; -.
DR   BioGRID-ORCS; 498; 550 hits in 1164 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; DEE660B4; Stress granule.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; ATP5A1; human.
DR   GenomeRNAi; 498; -.
DR   Pharos; P25705; Tbio.
DR   PRO; PR:P25705; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; P25705; protein.
DR   Bgee; ENSG00000152234; Expressed in heart right ventricle and 216 other cell types or tissues.
DR   ExpressionAtlas; P25705; baseline and differential.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:CAFA.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045259; C:proton-transporting ATP synthase complex; IDA:UniProtKB.
DR   GO; GO:0097229; C:sperm end piece; IDA:HPA.
DR   GO; GO:0043531; F:ADP binding; IBA:GO_Central.
DR   GO; GO:0043532; F:angiostatin binding; IPI:CAFA.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:Ensembl.
DR   GO; GO:0042288; F:MHC class I protein binding; IDA:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IEA:Ensembl.
DR   GO; GO:0046933; F:proton-transporting ATP synthase activity, rotational mechanism; IMP:CAFA.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0006754; P:ATP biosynthetic process; IMP:CAFA.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0071732; P:cellular response to nitric oxide; IEA:Ensembl.
DR   GO; GO:0006629; P:lipid metabolic process; ISS:UniProtKB.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IGI:CAFA.
DR   GO; GO:0015986; P:proton motive force-driven ATP synthesis; IDA:UniProtKB.
DR   GO; GO:0042776; P:proton motive force-driven mitochondrial ATP synthesis; IDA:UniProtKB.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0014850; P:response to muscle activity; IEA:Ensembl.
DR   CDD; cd18113; ATP-synt_F1_alpha_C; 1.
DR   CDD; cd18116; ATP-synt_F1_alpha_N; 1.
DR   CDD; cd01132; F1-ATPase_alpha_CD; 1.
DR   FunFam; 1.20.150.20:FF:000001; ATP synthase subunit alpha; 1.
DR   FunFam; 2.40.30.20:FF:000001; ATP synthase subunit alpha; 1.
DR   FunFam; 3.40.50.300:FF:002432; ATP synthase subunit alpha, mitochondrial; 1.
DR   Gene3D; 2.40.30.20; -; 1.
DR   Gene3D; 1.20.150.20; ATP synthase alpha/beta chain, C-terminal domain; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   HAMAP; MF_01346; ATP_synth_alpha_bact; 1.
DR   InterPro; IPR023366; ATP_synth_asu-like_sf.
DR   InterPro; IPR000793; ATP_synth_asu_C.
DR   InterPro; IPR038376; ATP_synth_asu_C_sf.
DR   InterPro; IPR033732; ATP_synth_F1_a_nt-bd_dom.
DR   InterPro; IPR005294; ATP_synth_F1_asu.
DR   InterPro; IPR020003; ATPase_a/bsu_AS.
DR   InterPro; IPR004100; ATPase_F1/V1/A1_a/bsu_N.
DR   InterPro; IPR036121; ATPase_F1/V1/A1_a/bsu_N_sf.
DR   InterPro; IPR000194; ATPase_F1/V1/A1_a/bsu_nucl-bd.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   NCBIfam; TIGR00962; atpA; 1.
DR   NCBIfam; NF009884; PRK13343.1; 1.
DR   PANTHER; PTHR48082; ATP SYNTHASE SUBUNIT ALPHA, MITOCHONDRIAL; 1.
DR   PANTHER; PTHR48082:SF2; ATP SYNTHASE SUBUNIT ALPHA, MITOCHONDRIAL; 1.
DR   Pfam; PF00006; ATP-synt_ab; 1.
DR   Pfam; PF00306; ATP-synt_ab_C; 1.
DR   Pfam; PF02874; ATP-synt_ab_N; 1.
DR   PIRSF; PIRSF039088; F_ATPase_subunit_alpha; 1.
DR   SUPFAM; SSF47917; C-terminal domain of alpha and beta subunits of F1 ATP synthase; 1.
DR   SUPFAM; SSF50615; N-terminal domain of alpha and beta subunits of F1 ATP synthase; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS00152; ATPASE_ALPHA_BETA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP synthesis;
KW   ATP-binding; Cell membrane; CF(1); Direct protein sequencing;
KW   Disease variant; Glycoprotein; Hydrogen ion transport; Ion transport;
KW   Membrane; Methylation; Mitochondrion; Mitochondrion inner membrane;
KW   Nucleotide-binding; Phosphoprotein; Primary mitochondrial disease;
KW   Proteomics identification; Reference proteome; Transit peptide;
KW   Translocase; Transport.
FT   TRANSIT         1..43
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000269|PubMed:19892738"
FT   CHAIN           44..553
FT                   /note="ATP synthase F(1) complex subunit alpha,
FT                   mitochondrial"
FT                   /id="PRO_0000002424"
FT   BINDING         215
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_note="ligand shared between homotrimeric partners"
FT                   /evidence="ECO:0000269|PubMed:37244256,
FT                   ECO:0007744|PDB:8H9V, ECO:0007744|PDB:8KI3"
FT   BINDING         217
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_note="ligand shared between homotrimeric partners"
FT                   /evidence="ECO:0000269|PubMed:37244256,
FT                   ECO:0007744|PDB:8H9V, ECO:0007744|PDB:8KI3"
FT   BINDING         218
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_note="ligand shared between homotrimeric partners"
FT                   /evidence="ECO:0000269|PubMed:37244256,
FT                   ECO:0007744|PDB:8H9V, ECO:0007744|PDB:8KI3"
FT   BINDING         219
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_note="ligand shared between homotrimeric partners"
FT                   /evidence="ECO:0000269|PubMed:37244256,
FT                   ECO:0007744|PDB:8H9V, ECO:0007744|PDB:8KI3"
FT   BINDING         219
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="ligand shared between homotrimeric partners"
FT                   /evidence="ECO:0000269|PubMed:37244256,
FT                   ECO:0007744|PDB:8H9V, ECO:0007744|PDB:8KI3"
FT   BINDING         220
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_note="ligand shared between homotrimeric partners"
FT                   /evidence="ECO:0000269|PubMed:37244256,
FT                   ECO:0007744|PDB:8H9V, ECO:0007744|PDB:8KI3"
FT   BINDING         312
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="ligand shared between homotrimeric partners"
FT                   /evidence="ECO:0000269|PubMed:37244256,
FT                   ECO:0007744|PDB:8H9V, ECO:0007744|PDB:8KI3"
FT   BINDING         473
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_note="ligand shared between homotrimeric partners"
FT                   /evidence="ECO:0000269|PubMed:37244256,
FT                   ECO:0007744|PDB:8H9V, ECO:0007744|PDB:8KI3"
FT   BINDING         475
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_note="ligand shared between homotrimeric partners"
FT                   /evidence="ECO:0000269|PubMed:37244256,
FT                   ECO:0007744|PDB:8H9V, ECO:0007744|PDB:8KI3"
FT   SITE            413
FT                   /note="Required for activity"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         53
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         65
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         76
FT                   /note="Phosphoserine; alternate"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         106
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         123
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         126
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         132
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         134
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P15999"
FT   MOD_RES         161
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         161
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         166
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         167
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         167
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         184
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         204
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         230
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         230
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         239
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         239
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         240
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         261
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         261
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         305
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         305
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         427
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         427
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         434
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         498
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         498
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         506
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         506
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         531
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         531
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         539
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         539
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   MOD_RES         541
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03265"
FT   CARBOHYD        76
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..50
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045129"
FT   VAR_SEQ         140..161
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054688"
FT   VARIANT         32
FT                   /note="A -> S (in dbSNP:rs2228437)"
FT                   /id="VAR_048369"
FT   VARIANT         182
FT                   /note="R -> Q (in MC5DN4A; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:34954817"
FT                   /id="VAR_088541"
FT   VARIANT         207
FT                   /note="R -> H (in MC5DN4A; likely pathogenic)"
FT                   /evidence="ECO:0000269|PubMed:34483339,
FT                   ECO:0000269|PubMed:34954817"
FT                   /id="VAR_088542"
FT   VARIANT         321
FT                   /note="Y -> C (in COXPD22; dbSNP:rs587777788)"
FT                   /evidence="ECO:0000269|PubMed:23596069"
FT                   /id="VAR_071982"
FT   VARIANT         329
FT                   /note="R -> C (in MC5DN4B; dbSNP:rs587776960)"
FT                   /evidence="ECO:0000269|PubMed:23599390"
FT                   /id="VAR_069769"
FT   VARIANT         346
FT                   /note="S -> F (in MC5DN4A; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:34954817"
FT                   /id="VAR_088543"
FT   CONFLICT        162
FT                   /note="G -> V (in Ref. 5; BAG63618)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        183
FT                   /note="I -> T (in Ref. 5; BAG63618)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        329
FT                   /note="R -> L (in Ref. 5; AAH39135)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        356
FT                   /note="N -> D (in Ref. 5; BAG63618)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        510
FT                   /note="A -> D (in Ref. 5; AAH11384)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        529
FT                   /note="D -> E (in Ref. 5; AAH11384)"
FT                   /evidence="ECO:0000305"
FT   STRAND          72..76
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          81..86
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          94..97
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          99..101
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          103..109
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          114..120
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          135..137
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          139..143
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           144..146
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          159..161
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          168..173
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           194..199
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          209..212
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          214..217
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           218..228
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           230..233
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          234..236
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          243..250
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           253..264
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   TURN            265..267
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           269..271
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          272..277
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           283..302
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          306..312
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           314..327
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           334..336
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           341..349
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   TURN            357..360
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          363..366
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          369..371
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           380..388
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          389..395
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           397..401
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   TURN            410..412
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   STRAND          414..417
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           418..421
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           424..441
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           444..446
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           450..452
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           455..471
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           481..492
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   TURN            495..498
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           501..503
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           504..518
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           520..529
FT                   /evidence="ECO:0007829|PDB:8H9V"
FT   HELIX           534..550
FT                   /evidence="ECO:0007829|PDB:8H9V"
SQ   SEQUENCE   553 AA;  59751 MW;  AA47BBB8EDA77EAC CRC64;
     MLSVRVAAAV VRALPRRAGL VSRNALGSSF IAARNFHASN THLQKTGTAE MSSILEERIL
     GADTSVDLEE TGRVLSIGDG IARVHGLRNV QAEEMVEFSS GLKGMSLNLE PDNVGVVVFG
     NDKLIKEGDI VKRTGAIVDV PVGEELLGRV VDALGNAIDG KGPIGSKTRR RVGLKAPGII
     PRISVREPMQ TGIKAVDSLV PIGRGQRELI IGDRQTGKTS IAIDTIINQK RFNDGSDEKK
     KLYCIYVAIG QKRSTVAQLV KRLTDADAMK YTIVVSATAS DAAPLQYLAP YSGCSMGEYF
     RDNGKHALII YDDLSKQAVA YRQMSLLLRR PPGREAYPGD VFYLHSRLLE RAAKMNDAFG
     GGSLTALPVI ETQAGDVSAY IPTNVISITD GQIFLETELF YKGIRPAINV GLSVSRVGSA
     AQTRAMKQVA GTMKLELAQY REVAAFAQFG SDLDAATQQL LSRGVRLTEL LKQGQYSPMA
     IEEQVAVIYA GVRGYLDKLE PSKITKFENA FLSHVVSQHQ ALLGTIRADG KISEQSDAKL
     KEIVTNFLAG FEA
//
